{"name":"4D Molecular Therapeutics","slug":"4d-molecular-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":85209000,"revenueGrowth":230194.6,"grossMargin":0,"rdSpend":0,"netIncome":-140109000,"cash":566711000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"4D-110","genericName":"4D-110","slug":"4d-110","indication":"Other","status":"phase_1"},{"name":"4D-310","genericName":"4D-310","slug":"4d-310","indication":"Other","status":"phase_1"},{"name":"4D-710","genericName":"4D-710","slug":"4d-710","indication":"Cystic fibrosis","status":"phase_2"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Aflibercept IVT","genericName":"Aflibercept IVT","slug":"aflibercept-ivt","indication":"Retinal diseases associated with pathological angiogenesis and vascular permeability (e.g., diabetic retinopathy, retinal vein occlusion, age-related macular degeneration)","status":"phase_2"}]}],"pipeline":[{"name":"4D-110","genericName":"4D-110","slug":"4d-110","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"4D-310","genericName":"4D-310","slug":"4d-310","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"4D-710","genericName":"4D-710","slug":"4d-710","phase":"phase_2","mechanism":"4D-710 is a gene therapy that uses an adeno-associated virus to deliver a functional copy of the CFTR gene to the lungs, correcting the underlying genetic defect in cystic fibrosis.","indications":["Cystic fibrosis"],"catalyst":""},{"name":"Aflibercept IVT","genericName":"Aflibercept IVT","slug":"aflibercept-ivt","phase":"phase_2","mechanism":"Aflibercept IVT is a vascular endothelial growth factor (VEGF) trap that binds and neutralizes VEGF and placental growth factor (PlGF) to inhibit pathological angiogenesis and vascular permeability.","indications":["Retinal diseases associated with pathological angiogenesis and vascular permeability (e.g., diabetic retinopathy, retinal vein occlusion, age-related macular degeneration)"],"catalyst":""}],"recentEvents":[],"realNews":[{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxPMk40OHRyNlhSMXMzM1RyZ19vSWp0eWs4MEZoR0lCMm02UkJ4X2VDYkM4NFg1dDlTbGVkSTNoN2NJMFZQN19PRkN2Zk1oQzh2TzA1bS1hWk5SajhxcFpTOGdFSnZCcDBjSjc0akJaU3dvTE5yV19qRG1DcjlQWUl4NDNQbUk1LVFiclZGaUJMc2Z6M05vYTJNOXJxQ3h0cjRod2hac21yWkhQQmoxbjFMZXByalBXeE5mUXFYVi15QWpIWkRTMFdpYVA3UXIwUHpWN1JzOHFKdFpHMzRYeDJuZnNUQ1IwQjhOc1V0NWFEaXU0cDFBSFpDa25MMFBfWHgtcnhrN1luUHB6cmNqZGNlajdtbnlTYVNITFhoZXVKZld6Slh0VDA1NzI0RTkwcjN6b1pNN2FxaUoyS0c0M3ZqbXBOaG0?oc=5","date":"2026-03-21","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Scholar Rock Holding (SRRK) and Acrivon Therapeutics, Inc. (ACRV) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Scholar Rock Holding (SRRK) and Acriv","sentiment":"neutral"},{"date":"2026-03-18","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPYUpBN1RXLWcxb01fSl9YbmhLWURwb0s2dXRucXAwWnVSN0VWUG9tbjJWQTZkRnRfWHhVVEkwOHdXd2hiSThBdGJnVGN2Q3AzUkZyQXNqWnNNZDZ3cm9aNjgwLXN2LUlXYUJfU2dNdm5RQ3lVWjZaV1ZsQVZuaXQtSFhEMzNMUUt3YVNCMDlKbzRxazVzUTFObG5RY1BUQmls?oc=5","date":"2026-01-09","type":"pipeline","source":"statnews.com","summary":"Up and down the ladder: The latest comings and goings - statnews.com","headline":"Up and down the ladder: The latest comings and goings","sentiment":"neutral"},{"date":"2026-01-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNTFUxSnNPV0J1UzVneVFveEhnbDh6ei1oM3lzSi04MmtiQ3hBNVE1Q0RtWlVTblRxVjlzdEttWlJiYzhkVjVXZl80SkwwLUEzMHlydklNM0hxY2ZuYVNJQnpKdEhyQnJMb2p5cWpEaG9nV1NIWExKT2QzOGs0cE40SVlNOEN2eFV3QmpzQmdyVjVhSHVXSnFydDVOaFZBdnpsZ1VDS2NUeUstRngwZjQyMHd4N2Ewc1hhSWJOcHI0Yw?oc=5","date":"2025-12-19","type":"trial","source":"Seeking Alpha","summary":"4D Molecular Therapeutics: Jury Still Out On CF Gene Therapy After Dense Data Drop (NASDAQ:FDMT) - Seeking Alpha","headline":"4D Molecular Therapeutics: Jury Still Out On CF Gene Therapy After Dense Data Drop (NASDAQ:FDMT)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxObkVTWmdJaDI2SGxOcHRFemF1VUpyeExiUDh0a3ZleEh6c2d4NlZ5SmdhNExLOWpZMVRhMl9ZRVBWXzNGa0pfYTFXcGFiVlUtYmp0VDVzSzF1S2hDbVJBd2dWX25sR0hRejhLRG91eDFkRXM0VUJiSllvV2ZsRWVLYkZsbWVEbjJPd0pXYm9wb0ZpSTJuMmRxM1RucW5KbVdTdEhYTTRZTEtsZVMzQld5TEhCNS1xQUgtM1NmVkRnMzZRdXZaRnZj?oc=5","date":"2025-11-04","type":"deal","source":"Ophthalmology Times","summary":"4DMT and Otsuka Pharmaceutical partner on 4D-150 in the greater Asia-Pacific region - Ophthalmology Times","headline":"4DMT and Otsuka Pharmaceutical partner on 4D-150 in the greater Asia-Pacific region","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxObUdkcHA2U3RJUGRVSXRpRlM3bGRCUEtlMXpET2NuVXU1QnFVQ3FQSmZpQW5yc21hYnZlTDFNSGp4VDcwdWRLdUJfQ3BJcTlSVEdRN0NCMmVCbWtqeUJ3Y00tdnJXT1J6dDZ0ZGd3MXJqZlBOaF8zdGt4VVQ0aGVaQlRRS3ZveHhLS2tjZlNjODdUUlB3UmNqMm5uVjQ5YmhqZ3c?oc=5","date":"2025-11-04","type":"deal","source":"Pharmaceutical Executive","summary":"Roundup: Biotech’s Most Recent Strategic Partnerships and Exclusive Licensing Agreements - Pharmaceutical Executive","headline":"Roundup: Biotech’s Most Recent Strategic Partnerships and Exclusive Licensing Agreements","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQT3JBZkpHV3ljREZFSzF2c1ZEMm9VR0JGcHh5S21DQnBONW1uM09DTlR6azhvcDJrRGVOb2ZkczBTT3FGYTQyZXJ4eVhKaWwwbHhZRHZaemFuU29aRWxqRU04MEM0RUhLZEtPRG1lSnd3VnB5Mm1kUjBMNVF4Y2FwWkxXaUxQdVdMRXFrb2lNc0lnUVM4Zk54ZmhISmNZdFl2aWs3SHJxSEJHT2s3dTdYRA?oc=5","date":"2025-10-31","type":"trial","source":"Fierce Biotech","summary":"4DMT eyes $420M deal from Otsuka, with cash aimed at retinal gene therapy's phase 3 plans - Fierce Biotech","headline":"4DMT eyes $420M deal from Otsuka, with cash aimed at retinal gene therapy's phase 3 plans","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBiV1Z1N3dsbmtnY1JiNWJYOTdLVmw1V0FLMTF4Y1VlNFg1U3QxMlRBSGJwQURfWGdoWllONFc4QlB3MG42d200bDZFeW1maHdiYVlz?oc=5","date":"2025-10-31","type":"pipeline","source":"FirstWord Pharma","summary":"Otsuka nabs Asia-Pacific rights to 4DMT's retinal gene therapy for $85M - FirstWord Pharma","headline":"Otsuka nabs Asia-Pacific rights to 4DMT's retinal gene therapy for $85M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxQcUU3eGRDQjNLYjM2M0I1OEF2ZG1ZaFBkVkxWUmFPQ0M3TlhqNXJZOTM5WmZraTJRNkxMS2tTZUFLbGY5RnAwMUN4enFlc19aUUJqRHd6LUtJaU5taGtlcTdUUkhlazBsTzc1SDBYM0JlSVRZN2dZbjBfQXZjOENodkN2czJIYTFnNklOY2xPN2hFOEJTT0NKTG9uZVc5Y2FZa3ZWdDdhZlZOUS0tTVFjZzl3WFROSDhmOU9jaXhSTWxGdk5WWnBxcFZscXZEQUI0Zk5VRGtEOFhuUU1iNmxSbTZQekItdk5CekttR2YxWkVWTE1aY0EwV3NnZUp6THVfS2NMYUZYVUVhY1Z0YWxhUlNzWF9YN3RTWkZnMS1EZ2dNQlFoNDZoWk5wWTU4Zi1ZdURsMnFhcw?oc=5","date":"2025-10-30","type":"deal","source":"GlobeNewswire","summary":"4DMT Announces Exclusive License Agreement with Otsuka - GlobeNewswire","headline":"4DMT Announces Exclusive License Agreement with Otsuka","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxQV3p0WXY5ZXdmOG1nQ0hYMFQyVWs2SDhvWjZYNm1XOGRBLXNPdzEtWGo5WTJvSVVRVi1icS05U1hQcUhGRGxGQWxxdF9qejJuWm1BYlRJT2dYaEVmTzkyclRQWllNSmVMSEZheW9TREtoQ05vTzUxQkdSSXE2UFFJOXNHSkNIU0RhU0szNVVTX1FIRU4zU1RLeWh6Q2d1LVZqRmIxNlJUZWFvSWplYWlWTjJoTW5DdnFYXy1Zc01QQzNiZmxSWVRjWU1ZQnFieE1sbDFwZG9JVGhOOVhZelpWM0ZMMXluU2VrdDBEVDliV0RyRmhZblVDREpvVkRhWGdhZTROUWZFaVlhM3FOWWJuRDZXemRkd21Tc2RDOEsxR3BHcW1saEItV1ZvUkxDendudDZBZHFwUlNCRzc2NVBCYmdrMzc?oc=5","date":"2025-08-28","type":"trial","source":"GlobeNewswire","summary":"Antisense Oligonucleotide Therapeutics Clinical Trial - GlobeNewswire","headline":"Antisense Oligonucleotide Therapeutics Clinical Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQRC0tTlFoSndSWlR4X3FXNWZiM292OVpnb0FvNHhTZ0d3by1fc0xjejFQeVcwdXh3dWVmN1VQZHF4Y0VPXy1HT3lNbzRmVE93NUl1MUpRRlBjdy14X0hKSTRlVFFVWjdxdHpMWjM4eU9ZaVhfc1hJWVVwdEh6cm9pRDh4U2k5Q0hRbzE0VEthdkxoYmhJVUN1d0xMTQ?oc=5","date":"2025-06-17","type":"trial","source":"Yahoo Finance","summary":"Oligonucleotides Clinical Trial Pipeline Analysis Demonstrates 280+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - Yahoo Finance","headline":"Oligonucleotides Clinical Trial Pipeline Analysis Demonstrates 280+ Key Companies at the Horizon Expected to Transform t","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_1":2,"phase_2":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":85209000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":85209000,"period":"2025-12-31"},{"value":37000,"period":"2024-12-31"},{"value":37000,"period":"2024-12-31"},{"value":20723000,"period":"2023-12-31"},{"value":20723000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-140109000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":566711000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}